Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'
Is the lower sale price making the opportunity for a priority review voucher less an incentive for orphan development?
You may also be interested in...
Researchers find no significant difference in number of rare pediatric disease treatments starting clinical development before or after incentive was created, but advocates aren't ready to give up on the program yet.
Sanofi executive offers five-year voucher life-span as potential option for sustaining the resale market.
Only the first publicly disclosed sale of a priority review voucher was lower than what Jazz Pharmaceuticals paid Spark Therapeutics for its coupon.